Indivior Pharmaceuticals, Inc. (INDV) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 6, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 3, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the INDV SEC filings page.
Indivior Pharmaceuticals, Inc. (INDV) reported $1.3B in revenue over the twelve months to Jun 30, 2026, up 13.5% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Profitability arrived in FY2025, but cash conversion broke down as reinvestment and balance-sheet pressure persisted.
The business moved from a net loss of$126M in FY2023 to$210M of profit in FY2025, while operating cash flow improved from-$300M to-$27M ; the earnings turnaround was real on the income statement but not yet cash-backed. Because capital spending also reached$66M , free cash flow was-$93M despite a21.2% operating margin—profitability is currently producing less cash than headline earnings imply.
Gross margin was broadly stable across the period, while operating margin swung from
The balance sheet is less strained than in FY2024: liabilities exceeded assets by
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Indivior Pharmaceuticals, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Indivior Pharmaceuticals, Inc. has an operating margin of 21.1%, meaning the company retains $21 of operating profit per $100 of revenue. This results in a moderate score of 45/100, indicating healthy but not exceptional operating efficiency. This is up from 3.2% the prior year.
Indivior Pharmaceuticals, Inc.'s revenue grew a modest 4.3% year-over-year to $1.2B. This slow but positive growth earns a score of 55/100.
Indivior Pharmaceuticals, Inc.'s current ratio of 0.71 is below the typical benchmark, resulting in a score of 8/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Indivior Pharmaceuticals, Inc.'s operations used $27.0M of cash, and capex of $66.0M added to the outflow, for a free cash flow shortfall of $93.0M. This results in a cash flow score of 13/100.
Indivior Pharmaceuticals, Inc. scores 3.16, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($4.2B) relative to total liabilities ($1.3B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Indivior Pharmaceuticals, Inc. passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Indivior Pharmaceuticals, Inc. used $0.13 of operating cash (-$27.0M OCF vs $210.0M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
Indivior Pharmaceuticals, Inc. earns $6.89 in operating income for every $1 of interest expense ($262.0M vs $38.0M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Indivior Pharmaceuticals, Inc. generated $343.0M in revenue in Q2 2026. This represents an increase of 13.6% from the same quarter a year earlier. Against the prior quarter it is up 8.2%.
Indivior Pharmaceuticals, Inc.'s EBITDA was $162.0M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 118.9% from the same quarter a year earlier. Against the prior quarter it is up 16.5%.
Indivior Pharmaceuticals, Inc. reported $122.0M in net income in Q2 2026. This represents an increase of 577.8% from the same quarter a year earlier. Against the prior quarter it is up 37.1%.
Indivior Pharmaceuticals, Inc. earned $0.98 per diluted share (EPS) in Q2 2026. This represents an increase of 600.0% from the same quarter a year earlier. Against the prior quarter it is up 42.0%.
Cash & Balance Sheet
Indivior Pharmaceuticals, Inc. generated $222.0M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 57.4% from the same quarter a year earlier. Against the prior quarter it is up 865.5%.
Indivior Pharmaceuticals, Inc. held $222.0M in cash against $487.0M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Indivior Pharmaceuticals, Inc.'s gross margin was 85.7% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 2.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.7 percentage points.
Indivior Pharmaceuticals, Inc.'s operating margin was 46.7% in Q2 2026, reflecting core business profitability. This is up 22.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.4 percentage points.
Indivior Pharmaceuticals, Inc.'s net profit margin was 35.6% in Q2 2026, showing the share of revenue converted to profit. This is up 29.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 7.5 percentage points.
Not reported for Q2 2026.
Capital Allocation
Indivior Pharmaceuticals, Inc. invested $12.0M in research and development in Q2 2026. This represents a decrease of 42.9% from the same quarter a year earlier. Against the prior quarter it is down 25.0%.
Indivior Pharmaceuticals, Inc. spent $177.0M on share buybacks in Q2 2026, returning capital to shareholders by reducing shares outstanding. Against the prior quarter it is up 41.6%.
Indivior Pharmaceuticals, Inc. invested $7.0M in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 58.8% from the same quarter a year earlier. Against the prior quarter it is down 65.0%.
INDV Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $343.0M+13.6% | $317.0M+19.2% | $357.0M+19.8% | $314.0M+2.3% | $302.0M+1.0% | $266.0M-6.3% | $298.0M | $307.0M |
| Cost of Revenue | $50.0M-3.8% | $40.0M-9.1% | $67.0M+39.6% | $83.0M+25.8% | $52.0M-34.2% | $44.0M+15.8% | $48.0M | $66.0M |
| Gross Profit | $294.0M+17.6% | $277.0M+25.3% | $293.0M+17.2% | $230.0M-4.6% | $250.0M+13.6% | $221.0M-10.2% | $250.0M | $241.0M |
| R&D Expenses | $12.0M-42.9% | $16.0M-27.3% | $21.0M-32.3% | $33.0M+50.0% | $21.0M-19.2% | $22.0M-21.4% | $31.0M | $22.0M |
| SG&A Expenses | $122.0M-22.8% | $124.0M-6.8% | $188.0M+7.4% | $155.0M+9.2% | $158.0M+3.9% | $133.0M-7.0% | $175.0M | $142.0M |
| Operating Income | $160.0M+122.2% | $137.0M+107.6% | $81.0M+76.1% | $43.0M+22.9% | $72.0M+161.0% | $66.0M-12.0% | $46.0M | $35.0M |
| EBITDA | $162.0M+118.9% | $139.0M+101.4% | $83.0M+62.7% | $46.0M+17.9% | $74.0M+163.8% | $69.0M-13.8% | $51.0M | $39.0M |
| Interest Expense | $2.0M-77.8% | $7.0M-22.2% | $11.0M+22.2% | $9.0M+28.6% | $9.0M+28.6% | $9.0M+28.6% | $9.0M | $7.0M |
| Income Tax | $38.0M-13.6% | $26.0M+136.4% | -$21.0M-223.5% | -$5.0M-162.5% | $44.0M+291.3% | $11.0M0.0% | $17.0M | $8.0M |
| Net Income | $122.0M+577.8% | $89.0M+89.4% | $103.0M+390.5% | $42.0M+90.9% | $18.0M+118.6% | $47.0M-23.0% | $21.0M | $22.0M |
| EPS (Basic) | $1.02+580.0% | $0.71+86.8% | $0.81+406.3% | $0.34+112.5% | $0.15+120.8% | $0.38-15.6% | $0.16 | $0.16 |
| EPS (Diluted) | $0.98+600.0% | $0.69+81.6% | $0.79+393.8% | $0.33+106.3% | $0.14+119.4% | $0.38-15.6% | $0.16 | $0.16 |
| Diluted Shares (Avg) | 124M-1.6% | 129M+3.2% | N/A | 129M-3.0% | 126M-6.7% | 125M-8.8% | N/A | 133M |
INDV Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.2B-15.1% | $1.2B-12.9% | $1.2B-8.7% | $1.4B | $1.5B | $1.4B | $1.3B-25.1% | N/A |
| Current Assets | $725.0M-23.8% | $667.0M-24.5% | $652.0M-21.2% | $922.0M | $951.0M | $883.0M | $827.0M-34.2% | N/A |
| Cash & Equivalents | $222.0M-56.5% | $175.0M-53.0% | $195.0M-38.9% | $445.0M+54.5% | $510.0M+68.9% | $372.0M+50.0% | $319.0M+0.9% | $288.0M |
| Short-Term Investments | $0 | $0-100.0% | $0-100.0% | $0 | $0 | $1.0M | $1.0M-98.9% | $0 |
| Inventory | $150.0M+0.7% | $152.0M-6.7% | $153.0M-8.4% | $155.0M | $149.0M | $163.0M | $167.0M+32.5% | N/A |
| Accounts Receivable | $271.0M+12.9% | $273.0M+12.3% | $253.0M-0.4% | $259.0M | $240.0M | $243.0M | $254.0M0.0% | N/A |
| Long-Term Investments | $27.0M0.0% | $27.0M0.0% | $28.0M+3.7% | $28.0M | $27.0M | $27.0M | $27.0M-34.1% | $0 |
| Goodwill | N/A | N/A | $2.0M0.0% | N/A | N/A | N/A | $2.0M-60.0% | N/A |
| Total Liabilities | $1.4B-15.7% | $1.3B-19.2% | $1.3B-21.3% | $1.6B | $1.7B | $1.7B | $1.7B-14.9% | N/A |
| Current Liabilities | $868.0M-17.8% | $779.0M-22.5% | $914.0M-1.1% | $965.0M | $1.1B | $1.0B | $924.0M-27.9% | N/A |
| Non-Current Liabilities | $573.0M-12.3% | $562.0M-14.2% | $386.0M-47.0% | $658.0M | $653.0M | $655.0M | $728.0M+10.1% | N/A |
| Long-Term Debt | $487.0M+58.1% | $486.0M+56.3% | $290.0M-7.9% | $304.0M | $308.0M | $311.0M | $315.0M+32.9% | N/A |
| Total Equity | -$208.0M+19.1% | -$144.0M+49.5% | -$98.0M+70.9% | -$207.0M+33.2% | -$257.0M+8.5% | -$285.0M-77.0% | -$337.0M-83.2% | -$310.0M |
| Retained Earnings | -$334.0M+13.9% | -$280.0M+31.0% | -$243.0M+45.1% | -$346.0M | -$388.0M | -$406.0M | -$443.0M-53.8% | N/A |
INDV Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $229.0M+44.9% | -$9.0M-112.0% | -$221.0M-1200.0% | -$39.0M-2050.0% | $158.0M+79.5% | $75.0M+302.7% | -$17.0M | $2.0M |
| Depreciation & Amortization | $2.0M0.0% | $2.0M-33.3% | $2.0M-60.0% | $3.0M-25.0% | $2.0M0.0% | $3.0M-40.0% | $5.0M | $4.0M |
| Stock-Based Compensation | $11.0M+37.5% | $9.0M+50.0% | N/A | $6.0M0.0% | $8.0M+33.3% | $6.0M0.0% | N/A | $6.0M |
| Capital Expenditures | $7.0M-58.8% | $20.0M+300.0% | $24.0M+50.0% | $20.0M+185.7% | $17.0M+325.0% | $5.0M+150.0% | $16.0M | $7.0M |
| Free Cash Flow | $222.0M+57.4% | -$29.0M-141.4% | -$245.0M-642.4% | -$59.0M-1080.0% | $141.0M+67.9% | $70.0M+279.5% | -$33.0M | -$5.0M |
| Investing Cash Flow | -$8.0M+52.9% | -$19.0M-280.0% | -$24.0M-400.0% | -$20.0M-157.1% | -$17.0M-1800.0% | -$5.0M-120.0% | $8.0M | $35.0M |
| Financing Cash Flow | -$173.0M-3360.0% | $7.0M+141.2% | -$5.0M-112.5% | -$3.0M+94.1% | -$5.0M+85.7% | -$17.0M+69.6% | $40.0M | -$51.0M |
| Share Buybacks | $177.0M | $125.0M+1036.4% | $0-100.0% | $0-100.0% | $0-100.0% | $11.0M-69.4% | $50.0M | $52.0M |
Not reported in any period shown, so not listed: Dividends Paid.
INDV Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 85.7%+2.9pp | 87.4%+4.3pp | 82.1%-1.8pp | 73.3%-5.2pp | 82.8%+9.2pp | 83.1%-3.5pp | 83.9% | 78.5% |
| Operating Margin | 46.7%+22.8pp | 43.2%+18.4pp | 22.7%+7.2pp | 13.7%+2.3pp | 23.8%+63.3pp | 24.8%-1.6pp | 15.4% | 11.4% |
| Net Margin | 35.6%+29.6pp | 28.1%+10.4pp | 28.8%+21.8pp | 13.4%+6.2pp | 6.0%+38.4pp | 17.7%-3.8pp | 7.0% | 7.2% |
| Return on Assets | 9.9%+8.7pp | 7.4%+4.0pp | 8.6%+7.0pp | 3.0% | 1.2% | 3.4% | 1.6% | N/A |
| Current Ratio | 0.84-0.1x | 0.860.0x | 0.71-0.2x | 0.96 | 0.90 | 0.88 | 0.90-0.1x | N/A |
| Asset Turnover | 0.28+0.1x | 0.26+0.1x | 0.30+0.1x | 0.22 | 0.21 | 0.19 | 0.23 | N/A |
| FCF Margin | 64.7%+18.0pp | -9.2%-35.5pp | -68.6%-57.6pp | -18.8%-17.2pp | 46.7%+18.6pp | 26.3%+40.0pp | -11.1% | -1.6% |
Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity.
Note: Shareholder equity is negative (-$98.0M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.71), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Indivior Pharmaceuticals, Inc. INDV | FY2025 | $1.2B | $210.0M | 17.0% | $4.2B | 44/100 |
| HUTCHMED (China) Limited HCM | FY2025 | $548.5M | $456.9M | 83.3% | $2.5B | 42/100 |
| Amneal Pharmaceuticals, Inc. AMRX | FY2025 | $3.0B | $72.1M | 2.4% | $7.1B | 56/100 |
| Bausch Health Companies Inc BHC | FY2025 | $10.3B | $157.0M | 1.5% | $2.2B | 51/100 |
| Supernus Pharmaceuticals, Inc. SUPN | FY2025 | $719.0M | -$38.6M | -5.4% | $2.5B | 53/100 |
| Kiniksa Pharmaceuticals International, plc KNSA | FY2025 | $677.6M | $59.0M | 8.7% | $6.0B | 64/100 |
Where Indivior Pharmaceuticals, Inc. Ranks
Frequently Asked Questions
What is Indivior Pharmaceuticals, Inc.'s annual revenue?
Indivior Pharmaceuticals, Inc. (INDV) reported $1.2B in total revenue for fiscal year 2025. This represents a 4.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Indivior Pharmaceuticals, Inc.'s revenue growing?
Indivior Pharmaceuticals, Inc. (INDV) revenue grew by 4.3% year-over-year, from $1.2B to $1.2B in fiscal year 2025.
Is Indivior Pharmaceuticals, Inc. profitable?
Yes, Indivior Pharmaceuticals, Inc. (INDV) reported a net income of $210.0M in fiscal year 2025, with a net profit margin of 17.0%.
What is Indivior Pharmaceuticals, Inc.'s EBITDA?
Indivior Pharmaceuticals, Inc. (INDV) had EBITDA of $272.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Indivior Pharmaceuticals, Inc. have?
As of fiscal year 2025, Indivior Pharmaceuticals, Inc. (INDV) had $195.0M in cash and equivalents against $290.0M in long-term debt.
What is Indivior Pharmaceuticals, Inc.'s gross margin?
Indivior Pharmaceuticals, Inc. (INDV) had a gross margin of 80.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Indivior Pharmaceuticals, Inc.'s operating margin?
Indivior Pharmaceuticals, Inc. (INDV) had an operating margin of 21.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Indivior Pharmaceuticals, Inc.'s net profit margin?
Indivior Pharmaceuticals, Inc. (INDV) had a net profit margin of 17.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Indivior Pharmaceuticals, Inc.'s free cash flow?
Indivior Pharmaceuticals, Inc. (INDV) recorded an outflow of $93.0M in free cash flow during fiscal year 2025. This represents a -1428.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Indivior Pharmaceuticals, Inc.'s operating cash flow?
Indivior Pharmaceuticals, Inc. (INDV) recorded an outflow of $27.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Indivior Pharmaceuticals, Inc.'s total assets?
Indivior Pharmaceuticals, Inc. (INDV) had $1.2B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Indivior Pharmaceuticals, Inc.'s capital expenditures?
Indivior Pharmaceuticals, Inc. (INDV) invested $66.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Indivior Pharmaceuticals, Inc. spend on research and development?
Indivior Pharmaceuticals, Inc. (INDV) invested $97.0M in research and development during fiscal year 2025.
What is Indivior Pharmaceuticals, Inc.'s current ratio?
Indivior Pharmaceuticals, Inc. (INDV) had a current ratio of 0.71 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Indivior Pharmaceuticals, Inc.'s return on assets (ROA)?
Indivior Pharmaceuticals, Inc. (INDV) had a return on assets of 17.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Indivior Pharmaceuticals, Inc.'s P/E ratio?
Indivior Pharmaceuticals, Inc. (INDV) trades at 11.9x earnings, its market capitalization divided by net income of $356.0M net income, trailing 12 months to June 30, 2026. The market capitalization is $4.2B as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Indivior Pharmaceuticals, Inc.'s price-to-sales ratio?
Indivior Pharmaceuticals, Inc. (INDV) trades at 3.2x sales, its market capitalization divided by revenue of $1.3B revenue, trailing 12 months to June 30, 2026. The market capitalization is $4.2B as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Indivior Pharmaceuticals, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Indivior Pharmaceuticals, Inc. (INDV) held $223.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $27.0M over that year. Dividing the one by the other, the reported balance equals about 99 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is Indivior Pharmaceuticals, Inc.'s debt-to-equity ratio negative or not reported?
Indivior Pharmaceuticals, Inc. (INDV) has negative shareholder equity of -$98.0M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Indivior Pharmaceuticals, Inc.'s Altman Z-Score?
Indivior Pharmaceuticals, Inc. (INDV) has an Altman Z-Score of 3.16, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Indivior Pharmaceuticals, Inc.'s Piotroski F-Score?
Indivior Pharmaceuticals, Inc. (INDV) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Indivior Pharmaceuticals, Inc.'s earnings high quality?
For every $1 of reported earnings, Indivior Pharmaceuticals, Inc. (INDV) used $0.13 of operating cash (-$27.0M OCF vs $210.0M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Indivior Pharmaceuticals, Inc. cover its interest payments?
Indivior Pharmaceuticals, Inc. (INDV) has an interest coverage ratio of 6.89x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Indivior Pharmaceuticals, Inc.?
Indivior Pharmaceuticals, Inc. (INDV) scores 44 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.